IMV — Imv Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- CA$13.12m
- CA$23.35m
- $0.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -174.04% | ||
| Return on Equity | -508.58% | ||
| Operating Margin | -11599.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.37 | 0.43 | 0.23 | 0.19 | 0.33 | n/a | n/a | 13.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IMV Inc. is a clinical-stage immuno-oncology company. The Company is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. It is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The Company is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Directors
- Andrew Sheldon NEC
- Andrew Hall CEO
- Pierre Labbe CFO (55)
- Jeremy Graff CSO
- Joanne Schindler OTH
- Michael Kalos DRC
- Michael Bailey IND (55)
- Julia Gregory IND (68)
- Kyle Kuvalanka IND (49)
- Shermaine Tilley IND
- Markus Warmuth IND
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- May 18th, 2007
- Public Since
- April 15th, 2004
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 11,711,637
- Address
- 130 Eileen Stubbs Ave Suite 19, DARTMOUTH, B3B 2C4
- Web
- https://imv-inc.com/
- Phone
- +1 9024921819
- Contact
- Joy Bessenger
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for IMV
Q2 2023 IMV Inc Earnings Release
Q3 2023 IMV Inc Earnings Release
Similar to IMV
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
FAQ
What is the Imv share price?
As of Today at 19:10 UTC, shares in Imv are trading at CA$1.12. This share price information is delayed by 15 minutes.
How has the Imv share price performed this year?
Shares in Imv last closed at CA$1.12 and the price had moved by -92.87% over the past 365 days. In terms of relative price strength the Imv share price has underperformed the Toronto Stock Exchange 300 Composite Index by -92.73% over the past year.
What are the analyst and broker recommendations for Imv?
The overall consensus recommendation for Imv is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Imv dividend yield?
Imv does not currently pay a dividend.
Does Imv pay a dividend?
Imv does not currently pay a dividend.
When does Imv next pay dividends?
Imv does not currently pay a dividend.
How do I buy Imv shares?
To buy shares in Imv you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Imv?
As of the previous close price of CA$1.12, shares in Imv had a market capitalisation of CA$13.12m.
Where are Imv shares listed?
Here are the trading details for Imv:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: IMV
What kind of share is Imv?
Based on an overall assessment of its quality, value and momentum Imv is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Imv share price forecast for 2023?
The analyst consensus target price for shares in Imv is CA$49.93. That is 4358.28% above the last closing price of CA$1.12.
Analysts covering Imv currently have a consensus Earnings Per Share (EPS) forecast of -$4.71 for the next financial year.
What is the trend in the Imv share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Imv. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -76.76%.
As of the last closing price of CA$1.12, shares in Imv were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Imv PE Ratio?
The Imv PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Imv?
Imv's management team is headed by:
- Andrew Sheldon - NEC
- Andrew Hall - CEO
- Pierre Labbe - CFO
- Jeremy Graff - CSO
- Joanne Schindler - OTH
- Michael Kalos - DRC
- Michael Bailey - IND
- Julia Gregory - IND
- Kyle Kuvalanka - IND
- Shermaine Tilley - IND
- Markus Warmuth - IND